The decreased serum activity of cytosolic 5'-nucleotidase IA as a potential marker of breast cancer-associated muscle inflammation

Nucleosides Nucleotides Nucleic Acids. 2022;41(3):273-284. doi: 10.1080/15257770.2021.2007396. Epub 2021 Nov 24.

Abstract

Cytosolic 5'-nucleotidase IA (cN-IA) plays a central role in the regulation of the purine nucleotide pool in skeletal muscle, preferentially converting adenosine monophosphate to adenosine. cN-IA can act as an autoantigen in muscle diseases, including the paraneoplastic syndrome related to breast cancer (BC). As a result of myocyte damage, released cN-IA protein may trigger the production of anti-cN-IA antibodies (anti-NT5C1A). This work aimed to develop an effective method to measure cN-IA activity in the serum and analyze it in BC patients. Our study demonstrated that serum cN-IA activity was decreased in BC patients and we assumed it is due to the presence of specific autoantibodies. We found correlations between cN-IA activity and parameters of inflammatory muscle damage. Thus, cN-IA is worth further attention to clarify its usefulness as a biomarker of BC-associated polymyositis.

Keywords: Cytosolic 5′-nucleotidase 1A; anti-NT5C1A autoantibody; breast cancer; cN-IA; polymyositis.

MeSH terms

  • 5'-Nucleotidase* / metabolism
  • Biomarkers
  • Breast Neoplasms*
  • Female
  • Humans
  • Inflammation
  • Muscles / metabolism

Substances

  • Biomarkers
  • 5'-Nucleotidase